Heidelberg Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jeffery Liu
Chief executive officer
€323.8k
Total compensation
| CEO salary percentage | 1.80% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 28 2026 | n/a | n/a | -€41m |
| Nov 30 2025 | €324k | €6k | -€42m |
| Aug 31 2025 | n/a | n/a | -€26m |
| May 31 2025 | n/a | n/a | -€23m |
| Feb 28 2025 | n/a | n/a | -€21m |
| Nov 30 2024 | €21k | n/a | -€19m |
| Aug 31 2024 | n/a | n/a | -€19m |
| May 31 2024 | n/a | n/a | -€13m |
| Feb 29 2024 | n/a | n/a | -€18m |
| Nov 30 2023 | €21k | n/a | -€20m |
| Aug 31 2023 | n/a | n/a | -€22m |
| May 31 2023 | n/a | n/a | -€27m |
| Feb 28 2023 | n/a | n/a | -€19m |
| Nov 30 2022 | €5k | n/a | -€20m |
Compensation vs Market: Jeffery's total compensation ($USD375.58K) is about average for companies of similar size in the German market ($USD452.86K).
Compensation vs Earnings: Jeffery's compensation has increased whilst the company is unprofitable.
CEO
Jeffery Liu
Dr. Dongzhou Liu, also known as Jeffery, Ph D, is CEO & Chairman of Executive Management Board of Heidelberg Pharma AG since December 2025 and had been its Member of Supervisory Board from June 28, 2022 un...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Executive Management Board | less than a year | €323.82k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 3.4yrs | no data | no data | |
| Director of Corporate Communications | no data | no data | no data | |
| Chief Medical Officer | 5.3yrs | no data | no data | |
| Chief Business Officer | no data | no data | no data |
Experienced Management: HPHA's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Chairman of the Supervisory Board | 26.4yrs | €40.11k | no data | |
| Member of Supervisory Board | 1.1yrs | €16.42k | no data | |
| Member of the Supervisory Board | 14.1yrs | €26.24k | no data | |
| Deputy Chairman of Supervisory Board | 10.9yrs | €36.25k | no data | |
| Chairman of Supervisory Board | 1.1yrs | €32.67k | no data | |
| Member of Supervisory Board | 2.4yrs | €19.50k | no data |
Experienced Board: HPHA's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 02:09 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2025/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Heidelberg Pharma AG is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruno Bulic | Baader Helvea Equity Research |
| Christian Weiz | Baader Helvea Equity Research |
| Robin Davison | Edison Investment Research |